Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.46 |
| ▸ | DRD4 | P21917 | 4/20 | 0.46 |
| ▸ | DRD3 | P35462 | 4/20 | 0.46 |
| ▸ | HTR1A | P08908 | 3/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | TNF | P01375 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7004173 | 0.86 | DRD2 (0.47) | DRD2DRD4DRD3HTR1AADRA1D | |
| SCHEMBL6616907 | 0.81 | DRD2 (0.46) | DRD2DRD4DRD3HTR1AADRA1D | |
| SCHEMBL6618313 | 0.79 | KDM4E (0.44) | DRD2DRD4DRD3HTR1AADRA1D | |
| SCHEMBL26967652 | 0.79 | DRD2 (0.51) | DRD2DRD4DRD3HTR1AADRA1D | |
| SCHEMBL29277966 | 0.79 | DRD2 (0.51) | DRD2DRD4DRD3HTR1AADRA1D | |
| SCHEMBL297697 | 0.77 | DRD2 (0.52) | DRD2DRD4DRD3HTR1AADRA1D | |
| SCHEMBL23554705 | 0.76 | KDM4E (0.40) | DRD2DRD4DRD3HTR1AADRA1D | |
| SCHEMBL18074770 | 0.76 | DRD2 (0.49) | DRD2DRD4DRD3HTR1AADRA1D | |
| SCHEMBL18074739 | 0.76 | DRD2 (0.49) | DRD2DRD4DRD3HTR1AADRA1D | |
| SCHEMBL12664330 | 0.76 | CXCR3 (0.50) | DRD2DRD4DRD3HTR1AADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820665-B2 | Imidazopyridazine inhibitors of PI3 kinase for cancer treatment | AMGEN INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-2231661-A1 | INHIBITORS OF PI3 KINASE | Amgen, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009085230-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090163489-A1 | Inhibitors of PI3 kinase | AMGEN INC. | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163489-A1 | Inhibitors of PI3 kinase | PIK3CA, PIK3CD, PIK3CG | DRD2 4833/4885DRD4 4847/4885DRD3 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.